Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- The material weakness in internal control over financial reporting could lead to significant misstatements, harming investor confidence.
- Sales of pen needles accounted for approximately $844 million, or 75%, of total net revenues, down from $912 million, or 81%.
- The ongoing geopolitical tensions, including the Israel-Hamas war, may disrupt supply chains and impact operations.
- The Italian Constitutional Court upheld the payback law, potentially increasing Embecta's liabilities related to medical device expenditures.
- The evolving regulatory landscape surrounding AI technologies may impose significant compliance costs and operational challenges for Embecta.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1872789&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.